Hepatocellular carcinoma Systemic therapy
Conditions
Interventions
Atezolizumab plus bevacizumab combination therapy
Sponsors
Ikeda Masafumi
JON-HBP
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Clinically diagnosed as hepatocellular carcinoma 2) Unsuitable for local therapy 3) Child-Pugh score of 7 or 8 4) 20 years old or older 5) ECOG Performance status of 0 or 1 6) Presence of target lesion 7) No prior systemic therapy 8) Preserved major organ function 9) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Active double cancer 2) Active infection requiring systemic treatments 3) Fever of 38 degrees celsius or higher 4) Pregnant or lactating women, or women of childbearing potential or her partner 5) Mental disorder 6) Autoimmune disease 7) Taking antiplatelet or anticoagulant medication 8) A history of hepatic encephalopathy within 3 months 9) Refractory ascites 10) Bleeding risk of esophageal and gastric varices 11) Metastases to central nervous system 12) Severe complication 13) Patients who investigator regards as inappropriate for candidate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severe adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver-related adverse events, immune-related adverse events, adverse events, trends of Child-Pugh scores and ALBI scores, objective response rate, progression-free survival, time to progression, overall survival | — |
Contacts
Public ContactMasafumi Ikeda
National Cancer Center Hospital East
Outcome results
None listed